{"id":9665,"date":"2026-03-18T11:12:29","date_gmt":"2026-03-18T03:12:29","guid":{"rendered":"https:\/\/regask.com\/?p=9665"},"modified":"2026-03-18T11:12:29","modified_gmt":"2026-03-18T03:12:29","slug":"la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","title":{"rendered":"La EMA abre el plazo de solicitud para el programa de cartera y tecnolog\u00eda de 2026\u2026"},"content":{"rendered":"<p><span data-contrast=\"auto\">En\u00a0<\/span><b><span data-contrast=\"auto\">10 de marzo de 2026<\/span><\/b><span data-contrast=\"auto\">, el\u00a0<\/span><b><span data-contrast=\"auto\">Agencia Europea de Medicamentos (EMA)<\/span><\/b><span data-contrast=\"auto\">\u00a0anunci\u00f3 que las solicitudes ya est\u00e1n abiertas para\u00a0<\/span><b><span data-contrast=\"auto\">Reuniones de cartera y tecnolog\u00eda (PTM)<\/span><\/b><span data-contrast=\"auto\">\u00a0programado para el\u00a0<\/span><b><span data-contrast=\"auto\">segunda mitad de 2026<\/span><\/b><span data-contrast=\"auto\">. El programa invita\u00a0<\/span><b><span data-contrast=\"auto\">Grandes compa\u00f1\u00edas farmac\u00e9uticas con amplias carteras de productos medicinales.<\/span><\/b><span data-contrast=\"auto\">\u00a0entablar conversaciones estructuradas con la agencia.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Estos\u00a0<\/span><b><span data-contrast=\"auto\">reuniones virtuales gratuitas<\/span><\/b><span data-contrast=\"auto\">\u00a0est\u00e1n dise\u00f1ados para abordar\u00a0<\/span><b><span data-contrast=\"auto\">desaf\u00edos en el desarrollo de la cartera de productos<\/span><\/b><span data-contrast=\"auto\">, captura\u00a0<\/span><b><span data-contrast=\"auto\">tecnolog\u00edas emergentes y disruptivas<\/span><\/b><span data-contrast=\"auto\">, y ayudar a la EMA a anticipar la\u00a0<\/span><b><span data-contrast=\"auto\">Se requieren conocimientos cient\u00edficos y regulatorios para futuras solicitudes de autorizaci\u00f3n de comercializaci\u00f3n.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Las empresas interesadas en participar deben presentar la informaci\u00f3n designada.\u00a0<\/span><b><span data-contrast=\"auto\">Formulario de solicitud PTM antes del 30 de abril de 2026.<\/span><\/b><span data-contrast=\"auto\">.La EMA revisar\u00e1 las solicitudes y notificar\u00e1 a los solicitantes el resultado.\u00a0<\/span><b><span data-contrast=\"auto\">para finales de mayo de 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><\/p>\n<div class=\"row\"  id=\"row-1241106051\">\n\n\t<div id=\"col-915059022\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-653604581\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-653604581 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>Detalles de la actualizaci\u00f3n<\/h2>\n\t<div id=\"gap-1648468801\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1648468801 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">El\u00a0<\/span><b><span data-contrast=\"auto\">Reuniones de cartera y tecnolog\u00eda (PTM)<\/span><\/b><span data-contrast=\"auto\">\u00a0brindar una oportunidad para que las grandes compa\u00f1\u00edas farmac\u00e9uticas discutan\u00a0<\/span><b><span data-contrast=\"auto\">Consideraciones regulatorias y cient\u00edficas para toda la cartera de productos.<\/span><\/b><span data-contrast=\"auto\">\u00a0directamente con la EMA. Las reuniones se llevan a cabo\u00a0<\/span><b><span data-contrast=\"auto\">virtualmente y sin costo para los solicitantes<\/span><\/b><span data-contrast=\"auto\">, reduciendo las barreras a la participaci\u00f3n y facilitando al mismo tiempo el compromiso estrat\u00e9gico.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">El programa est\u00e1 dise\u00f1ado espec\u00edficamente para ayudar a identificar\u00a0<\/span><b><span data-contrast=\"auto\">problemas que afectan al progreso de la cartera de productos<\/span><\/b><span data-contrast=\"auto\">\u00a0y facilitar el di\u00e1logo sobre\u00a0<\/span><b><span data-contrast=\"auto\">tecnolog\u00edas innovadoras y disruptivas<\/span><\/b><span data-contrast=\"auto\">\u00a0que pueden influir en futuras evaluaciones regulatorias. A trav\u00e9s de estas discusiones, la EMA pretende alinear sus\u00a0<\/span><b><span data-contrast=\"auto\">competencias cient\u00edficas y regulatorias<\/span><\/b><span data-contrast=\"auto\">\u00a0con las necesidades cambiantes de los oleoductos de la industria.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Si se concede una solicitud de reuni\u00f3n, los solicitantes deben presentar un\u00a0<\/span><b><span data-contrast=\"auto\">documento informativo completo<\/span><\/b><span data-contrast=\"auto\">\u00a0utilizando el\u00a0<\/span><b><span data-contrast=\"auto\">Plantilla proporcionada por la EMA (N\u00famero de referencia: EMA\/571070\/2023)<\/span><\/b><span data-contrast=\"auto\">. Este documento debe ser entregado\u00a0<\/span><b><span data-contrast=\"auto\">De cuatro a seis semanas antes de la reuni\u00f3n programada a trav\u00e9s de Eudralink.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Adem\u00e1s, los solicitantes deben presentar un\u00a0<\/span><b><span data-contrast=\"auto\">Presentaci\u00f3n previa a la reuni\u00f3n y lista de participantes una semana antes de la fecha de la reuni\u00f3n.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-915059022 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-98752333\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Fecha l\u00edmite para comentarios<\/h2>\n\t<div id=\"gap-1662373204\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1662373204 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">El\u00a0<\/span><b><span data-contrast=\"auto\">La fecha l\u00edmite para presentar el formulario de solicitud para la Reuni\u00f3n de Portafolio y Tecnolog\u00eda es el 30 de abril de 2026.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">El\u00a0<\/span><b><span data-contrast=\"auto\">La Agencia Europea de Medicamentos comunicar\u00e1 los resultados de las solicitudes y los pr\u00f3ximos pasos a finales de mayo de 2026.<\/span><\/b><span data-contrast=\"auto\">, con reuniones aprobadas programadas para tener lugar durante el\u00a0<\/span><b><span data-contrast=\"auto\">segunda mitad de 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-98752333 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-750484779\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Por qu\u00e9 es importante<\/h2>\n\t<div id=\"gap-1233658659\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1233658659 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">El\u00a0<\/span><b><span data-contrast=\"auto\">Programa PTM<\/span><\/b><span data-contrast=\"auto\">\u00a0ofrece una oportunidad estructurada para empresas con\u00a0<\/span><b><span data-contrast=\"auto\">grandes carteras de productos medicinales<\/span><\/b><span data-contrast=\"auto\">\u00a0abordar\u00a0<\/span><b><span data-contrast=\"auto\">desaf\u00edos del desarrollo interdepartamental y tecnolog\u00edas emergentes<\/span><\/b><span data-contrast=\"auto\">\u00a0con los reguladores en una etapa temprana.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Al permitir un di\u00e1logo temprano, la iniciativa apoya\u00a0<\/span><b><span data-contrast=\"auto\">estrategia regulatoria proactiva<\/span><\/b><span data-contrast=\"auto\">, mejora\u00a0<\/span><b><span data-contrast=\"auto\">alineaci\u00f3n en las expectativas cient\u00edficas<\/span><\/b><span data-contrast=\"auto\">, y ayuda a reducir\u00a0<\/span><b><span data-contrast=\"auto\">incertidumbre regulatoria futura<\/span><\/b><span data-contrast=\"auto\">\u00a0en carteras complejas, incluyendo\u00a0<\/span><b><span data-contrast=\"auto\">nuevas modalidades, productos biol\u00f3gicos y terapias avanzadas<\/span><\/b><span data-contrast=\"auto\">. El\u00a0<\/span><b><span data-contrast=\"auto\">formato virtual y gratuito<\/span><\/b><span data-contrast=\"auto\">\u00a0Mejora a\u00fan m\u00e1s la accesibilidad para las organizaciones que cumplen los requisitos.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-750484779 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-103202167\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Para qui\u00e9n es relevante<\/h2>\n\t<div id=\"gap-1297450404\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1297450404 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Este anuncio es particularmente relevante para <strong>Equipos de Asuntos Regulatorios, Asuntos M\u00e9dicos, Investigaci\u00f3n y Desarrollo y Comerciales<\/strong> dentro de las compa\u00f1\u00edas farmac\u00e9uticas gestionando <strong>amplias carteras de productos medicinales<\/strong>. Estas funciones desempe\u00f1an un papel fundamental en la preparaci\u00f3n de las solicitudes de PTM, la identificaci\u00f3n de problemas que afectan a toda la cartera de productos y la coordinaci\u00f3n de los materiales informativos que abordan las consideraciones cient\u00edficas, regulatorias y estrat\u00e9gicas de la cartera de productos.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-103202167 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1510574966\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Pr\u00f3ximos pasos<\/h2>\n\t<div id=\"gap-1701222923\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1701222923 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Las organizaciones que planean participar deben iniciar la coordinaci\u00f3n interna con anticipaci\u00f3n para garantizar la preparaci\u00f3n y presentaci\u00f3n oportunas de la documentaci\u00f3n.\u00a0<\/span><b><span data-contrast=\"auto\">Formulario de solicitud para la Reuni\u00f3n de Portafolio y Tecnolog\u00eda (PTM) antes del 30 de abril de 2026.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Equipos de Asuntos Regulatorios<\/span><\/b><span data-contrast=\"auto\">\u00a0primero debe evaluar\u00a0<\/span><b><span data-contrast=\"auto\">elegibilidad de la cartera<\/span><\/b><span data-contrast=\"auto\">, complete y env\u00ede el\u00a0<\/span><b><span data-contrast=\"auto\">Aplicaci\u00f3n PTM<\/span><\/b><span data-contrast=\"auto\">, y, si se aprueba la solicitud de reuni\u00f3n, coordinar la preparaci\u00f3n de la\u00a0<\/span><b><span data-contrast=\"auto\">Documento informativo de la EMA (EMA\/571070\/2023)<\/span><\/b><span data-contrast=\"auto\">\u00a0y gestionar el\u00a0<\/span><b><span data-contrast=\"auto\">Enviar la informaci\u00f3n a trav\u00e9s de Eudralink entre cuatro y seis semanas antes de la reuni\u00f3n programada.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Equipos de Asuntos M\u00e9dicos<\/span><\/b><span data-contrast=\"auto\">\u00a0deber\u00eda identificar\u00a0<\/span><b><span data-contrast=\"auto\">cuestiones cient\u00edficas y de desarrollo que abarcan toda la cartera de proyectos<\/span><\/b><span data-contrast=\"auto\">\u00a0que puede requerir debate regulatorio y trabajar en estrecha colaboraci\u00f3n con Asuntos Regulatorios para dar forma a la\u00a0<\/span><b><span data-contrast=\"auto\">Agenda de la reuni\u00f3n y aportaciones para la sesi\u00f3n informativa<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Equipos de Investigaci\u00f3n y Desarrollo<\/span><\/b><span data-contrast=\"auto\">\u00a0deber\u00eda contribuir\u00a0<\/span><b><span data-contrast=\"auto\">para canalizar datos y temas relacionados con la tecnolog\u00eda<\/span><\/b><span data-contrast=\"auto\">, incluido\u00a0<\/span><b><span data-contrast=\"auto\">modalidades novedosas o disruptivas<\/span><\/b><span data-contrast=\"auto\">, para su inclusi\u00f3n en el\u00a0<\/span><b><span data-contrast=\"auto\">Documento informativo y presentaci\u00f3n previa a la reuni\u00f3n<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"4\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Equipos comerciales y de marketing<\/span><\/b><span data-contrast=\"auto\">\u00a0deber\u00eda aportar informaci\u00f3n sobre\u00a0<\/span><b><span data-contrast=\"auto\">Prioridades de la estrategia de cartera y la gesti\u00f3n del ciclo de vida<\/span><\/b><span data-contrast=\"auto\">\u00a0que pueden beneficiarse de\u00a0<\/span><b><span data-contrast=\"auto\">alineaci\u00f3n cient\u00edfica temprana con la Agencia Europea de Medicamentos<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><b><span data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/es\/\">RegASK<\/a>\u00a0es una plataforma l\u00edder de inteligencia regulatoria y orquestaci\u00f3n de flujos de trabajo con inteligencia artificial de agencia.<\/span><\/b><span data-contrast=\"auto\">\u00a0que empodera a las organizaciones globales en sectores altamente regulados, incluyendo productos de consumo y ciencias de la vida, para navegar proactivamente en entornos regulatorios complejos. Al combinar\u00a0<\/span><b><span data-contrast=\"auto\">IA avanzada de Agentic con expertos en el circuito<\/span><\/b><span data-contrast=\"auto\">,\u00a0<a href=\"http:\/\/regask.com\/es\/\">RegASK<\/a>\u00a0entrega\u00a0<\/span><b><span data-contrast=\"auto\">Informaci\u00f3n predictiva y procesable oportuna y automatizaci\u00f3n de extremo a extremo<\/span><\/b><span data-contrast=\"auto\">, ayudando a los equipos a realizar un seguimiento de las iniciativas regulatorias, como los programas de colaboraci\u00f3n de la EMA, preparar la documentaci\u00f3n de manera eficiente y optimizar el cumplimiento en m\u00e1s de\u00a0<\/span><b><span data-contrast=\"auto\">160 pa\u00edses<\/span><\/b><span data-contrast=\"auto\">. <a href=\"http:\/\/regask.com\/es\/\"><strong>M\u00e1s informaci\u00f3n <\/strong><\/a>o<a href=\"https:\/\/regask.com\/es\/reservar-una-demostracion\/\"><strong> Reserve una demostraci\u00f3n ahora.<\/strong><\/a><\/span><strong>\u00a0<\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1510574966 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-882936872\">\n\n\t<div id=\"col-869079436\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>Preguntas frecuentes<\/h3>\n\t<div id=\"gap-636920417\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-636920417 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4><span class=\"TextRun MacChromeBold SCXW267956491 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW267956491 BCX0\" data-ccp-parastyle=\"heading 3\">\u00bfCu\u00e1les son las nuevas directrices del CDE sobre los ensayos cl\u00ednicos de la vacuna contra la gripe?<\/span><\/span><span class=\"EOP SCXW267956491 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-748112622\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-748112622 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><strong>Reuniones de cartera y tecnolog\u00eda (PTM)<\/strong> son reuniones virtuales estructuradas organizadas por el <strong>Agencia Europea de Medicamentos<\/strong> para permitir que las grandes compa\u00f1\u00edas farmac\u00e9uticas discutan <strong>Desaf\u00edos en el desarrollo de la cartera de productos y tecnolog\u00edas emergentes<\/strong> con el regulador.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-869079436 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-717827471\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW184197477 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW184197477 BCX0\" data-ccp-parastyle=\"heading 3\">\u00bfQui\u00e9nes pueden solicitar participar en las reuniones de EMA sobre cartera de proyectos y tecnolog\u00eda?<\/span><\/span><span class=\"EOP SCXW184197477 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-115723641\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-115723641 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>El programa PTM est\u00e1 abierto a <strong>Grandes compa\u00f1\u00edas farmac\u00e9uticas con amplias carteras de productos medicinales.<\/strong> Las empresas que cumplan los requisitos deber\u00e1n presentar un formulario de solicitud a la EMA para su revisi\u00f3n.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-717827471 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1467320723\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW3460145 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW3460145 BCX0\" data-ccp-parastyle=\"heading 3\">\u00bfCu\u00e1l es el plazo para solicitar una beca PTM en 2026?<\/span><\/span><span class=\"EOP SCXW3460145 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-2117173994\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2117173994 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>El <strong>La fecha l\u00edmite para presentar la solicitud es el 30 de abril de 2026.<\/strong> El <strong>La EMA comunicar\u00e1 los resultados de las solicitudes a finales de mayo de 2026.,<\/strong> y las reuniones aprobadas tendr\u00e1n lugar en el <strong>segunda mitad de 2026. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1467320723 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1537117290\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW14904628 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">\u00bfC\u00f3mo puedo?\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">RegASK<\/span><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">\u00a0\u00bfC\u00f3mo ayudan las organizaciones a gestionar actualizaciones como esta?<\/span><\/span><span class=\"EOP SCXW14904628 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1716569395\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1716569395 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/es\/\"><strong><span class=\"NormalTextRun SpellingErrorV2Themed SCXW253285960 BCX0\">RegASK<\/span><\/strong><\/a><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0<strong>Plataforma de inteligencia regulatoria basada en IA con agentes<\/strong><\/span><\/span><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">ayuda a las compa\u00f1\u00edas farmac\u00e9uticas\u00a0<\/span><\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">monitor<\/span><strong><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">Anuncios regulatorios globales, oportunidades de participaci\u00f3n y programas de consulta.<\/span><\/span><\/strong><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0en tiempo real. Esto permite a los equipos reguladores\u00a0<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">identificar<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0iniciativas como\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">Reuniones sobre la cartera de productos y la tecnolog\u00eda de la EMA<\/span><\/span><\/strong><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\"><strong>,<\/strong> coordinar la preparaci\u00f3n interna y\u00a0<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">mantener<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0Preparaci\u00f3n para el cumplimiento normativo en oleoductos globales complejos.<\/span><\/span><span class=\"EOP SCXW253285960 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1537117290 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>El 10 de marzo de 2026, la Agencia Europea de Medicamentos (EMA) anunci\u00f3 que ya est\u00e1 abierto el plazo de solicitud para las Reuniones de Cartera y Tecnolog\u00eda (PTM, por sus siglas en ingl\u00e9s) programadas para el segundo semestre de 2026. El programa invita a las grandes compa\u00f1\u00edas farmac\u00e9uticas con amplias carteras de medicamentos a participar en debates estructurados con la agencia. Estas reuniones virtuales y gratuitas est\u00e1n dise\u00f1adas para abordar los retos del desarrollo de la cartera de productos, identificar tecnolog\u00edas emergentes e innovadoras y ayudar a\u2026<\/p>","protected":false},"author":43,"featured_media":9666,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,538,35],"tags":[],"class_list":["post-9665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-european-union","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>EMA Opens Applications for 2026 Portfolio Meetings<\/title>\n<meta name=\"description\" content=\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA Opens Applications for 2026 Portfolio and Technology Meetings for Large Pharmaceutical Companies\" \/>\n<meta property=\"og:description\" content=\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T03:12:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"EMA Opens Applications for 2026 Portfolio and Technolog&hellip;\",\"datePublished\":\"2026-03-18T03:12:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"},\"wordCount\":1002,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"articleSection\":[\"Regulatory News\",\"European Union\",\"Pharma and Biotech\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\",\"name\":\"EMA Opens Applications for 2026 Portfolio Meetings\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"datePublished\":\"2026-03-18T03:12:29+00:00\",\"description\":\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"width\":800,\"height\":600,\"caption\":\"Ema Opens Applications 2026 Portfolio Technology Meetings Large Pharmaceutical Companies\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"La EMA abre el plazo de solicitud para las reuniones de cartera de 2026.","description":"La EMA abre el plazo de solicitud para las Reuniones de Cartera y Tecnolog\u00eda de 2026 dirigidas a grandes empresas farmac\u00e9uticas. El plazo de solicitud finaliza el 30 de abril.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas\/","og_locale":"es_ES","og_type":"article","og_title":"EMA Opens Applications for 2026 Portfolio and Technology Meetings for Large Pharmaceutical Companies","og_description":"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.","og_url":"https:\/\/regask.com\/es\/la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-03-18T03:12:29+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#article","isPartOf":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"EMA Opens Applications for 2026 Portfolio and Technolog&hellip;","datePublished":"2026-03-18T03:12:29+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"},"wordCount":1002,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","articleSection":["Regulatory News","European Union","Pharma and Biotech"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","url":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","name":"La EMA abre el plazo de solicitud para las reuniones de cartera de 2026.","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","datePublished":"2026-03-18T03:12:29+00:00","description":"La EMA abre el plazo de solicitud para las Reuniones de Cartera y Tecnolog\u00eda de 2026 dirigidas a grandes empresas farmac\u00e9uticas. El plazo de solicitud finaliza el 30 de abril.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","width":800,"height":600,"caption":"Ema Opens Applications 2026 Portfolio Technology Meetings Large Pharmaceutical Companies"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"El sistema operativo de IA regulatoria para equipos de alto rendimiento","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/9665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=9665"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/9665\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/9666"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=9665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=9665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=9665"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}